| Paclitaxel (taxol) EK Rowinsky, RC Donehower New England journal of medicine 332 (15), 1004-1014, 1995 | 2871 | 1995 |
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ... Nature 486 (7404), 532-536, 2012 | 2113 | 2012 |
| EFNS guidelines on pharmacological treatment of neuropathic pain N Attal, G Cruccu, M Haanpää, P Hansson, TS Jensen, T Nurmikko, ... European journal of neurology 13 (11), 1153-1169, 2006 | 1476 | 2006 |
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016 | 1058 | 2016 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017 | 853 | 2017 |
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ... British journal of cancer 101 (4), 715-721, 2009 | 722 | 2009 |
| EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients F Cappuzzo, G Finocchiaro, E Rossi, PA Jänne, C Carnaghi, C Calandri, ... Annals of Oncology 19 (4), 717-723, 2008 | 330 | 2008 |
| Assessment of a HER2 scoring system for colorectal cancer: results from a validation study E Valtorta, C Martino, A Sartore-Bianchi, F Penaullt-Llorca, G Viale, ... Modern Pathology 28 (11), 1481-1491, 2015 | 317 | 2015 |
| Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ... Science translational medicine 6 (224), 224ra26-224ra26, 2014 | 299 | 2014 |
| Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer A Amatu, A Sartore-Bianchi, K Bencardino, EG Pizzutilo, F Tosi, S Siena Annals of Oncology 30, viii5-viii15, 2019 | 283 | 2019 |
| Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer L Barault, A Amatu, G Siravegna, A Ponzetti, S Moran, A Cassingena, ... Gut 67 (11), 1995-2005, 2018 | 230 | 2018 |
| Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial A Sartore-Bianchi, S Lonardi, C Martino, E Fenocchio, F Tosi, S Ghezzi, ... ESMO open 5 (5), e000911, 2020 | 151 | 2020 |
| Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis F Tosi, E Magni, A Amatu, G Mauri, K Bencardino, M Truini, S Veronese, ... Clinical colorectal cancer 16 (3), e153-e163, 2017 | 136 | 2017 |
| Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer A Amatu, A Sartore-Bianchi, C Moutinho, A Belotti, K Bencardino, ... Clinical cancer research 19 (8), 2265-2272, 2013 | 129 | 2013 |
| Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer … M Ronzoni, M Manzoni, S Mariucci, F Loupakis, S Brugnatelli, ... Annals of oncology 21 (12), 2382-2389, 2010 | 123 | 2010 |
| A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced … A Santoro, V Gebbia, T Pressiani, A Testa, N Personeni, EA Bajardi, ... Annals of Oncology 26 (3), 542-547, 2015 | 113 | 2015 |
| EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer G Finocchiaro, F Cappuzzo, PA Janne, K Bencardino, C Carnaghi, ... Journal of Clinical Oncology 25 (18_suppl), 4021-4021, 2007 | 112 | 2007 |
| Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies G Mauri, EG Pizzutilo, A Amatu, K Bencardino, L Palmeri, EF Bonazzina, ... Cancer treatment reviews 73, 41-53, 2019 | 94 | 2019 |
| Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer F Loupakis, A Ruzzo, L Salvatore, C Cremolini, G Masi, P Frumento, ... BMC cancer 11, 1-9, 2011 | 87 | 2011 |
| Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer F Tosi, A Sartore-Bianchi, S Lonardi, A Amatu, F Leone, S Ghezzi, ... Clinical colorectal cancer 19 (4), 256-262. e2, 2020 | 86 | 2020 |